Fast Track Initiative

Hiromichi Kimura, the Founder & Managing Partner, and Tomohiro Anzai, the Managing Partner, lead the firm. Kimura’s background is in science, while Anzai transitioned into venture after his own attempts to commercialize academic research fell short, an experience that explicitly shapes the firm’s thesis.

The firm focuses on early-stage companies, often entering at or before company formation. It works with researchers on patenting, business planning, and initial capital raising, blurring the line between a traditional seed-stage investor and a venture builder.

FTI invests solely in life sciences and healthcare. Its portfolio is divided into three segments: biotech (cell therapy, RNA editing, microbiome therapeutics), medtech (therapeutic ultrasound, surgical robotics, drug-eluting stents), and healthtech (digital health platforms, genomics services, wearables).

While headquartered in Tokyo, the firm maintains a geographically diverse portfolio. Publicly disclosed investees are headquartered in Japan, the United States (California and Massachusetts), and the United Kingdom (Cambridge), reflecting an effort to back globally competitive science regardless of origin.

Based on the firm’s public disclosures, it operates as a direct investor into operating companies. There is no indication in its published materials that it makes fund-of-funds commitments or invests through special purpose vehicles on behalf of limited partners.

Portfolio press releases indicate FTI regularly syndicates with other venture firms. For example, Sonire Therapeutics' Series A round was led by an overseas VC alongside FTI, suggesting the firm is comfortable serving as a co-investor in larger financing rounds.

No philanthropic foundations, club memberships, or separate operating companies are disclosed in the firm’s public materials. The website presents Fast Track Initiative as a standalone venture capital entity with no disclosed adjacent vehicles.